SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant market volatility and high trading volume as investors react to a transformational earnings report featuring robust revenue guidance and the integration of its recent acquisition. The community is actively debating the timing of potential major contract awards, with bullish sentiment driven by the company's ambitious 2026 outlook and its unique position in lunar infrastructure, while short sellers remain focused on execution risks and past delays.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently seeing volatile trading as investors weigh concerns over Medicare Advantage reimbursement rates and regulatory pressures against the company's long-term potential as a defensive sector leader. The community is actively debating whether current price levels represent a significant buying opportunity ahead of upcoming policy decisions, with many participants closely monitoring institutional positioning and sector-wide sentiment.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings shares are facing volatility as the market reacts to intense competition from prediction markets like Kalshi and Polymarket, which are currently fueling debate over regulatory oversight and their long-term impact on traditional sportsbook revenue. While DraftKings is leaning into its own 'Super App' strategy to capture market share and enhance margins, community sentiment remains split between investors betting on a sports-betting rebound and those concerned by persistent insider selling and the broader threat to the existing legislative moat.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Este Lauder is trending following reports that it is nearing a merger deal with Puig, the parent company of Jean Paul Gaultier, sparking intense community debate over the potential impact on shareholder value. While some investors view the deal as a significant turnaround catalyst, others are actively questioning whether the merger will leave existing shareholders with diluted equity or meaningful long-term upside.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and aggressive upside momentum as retail traders speculate on its high-profile private equity holdings like Anthropic, OpenAI, and SpaceX. While the community is debating the stock's massive premium over its net asset value and the impact of a six-month lockup period on the majority of existing shares, many are actively monitoring technical chart patterns and volume spikes to identify entry and exit points for what they perceive as a high-risk, high-reward trading opportunity.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE token is sparking polarized debate as traders contrast its resilience against broader market volatility with concerns regarding its speculative nature. Community sentiment remains split between those observing quiet accumulation patterns and those skeptical of its long-term viability.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing significant volatility and a sharp sell-off, driven by a combination of surging bond yields, a strengthening dollar, and massive capital rotation into the energy sector amid escalating Middle East tensions. Community sentiment is deeply divided, with some investors panic-selling as gold loses its safe-haven appeal, while others view the heavy liquidation and extreme oversold conditions as a rare contrarian buying opportunity for long-term physical accumulation.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending due to its aggressive global expansion, including commercial robotaxi operations with Uber in the Middle East and new autonomous vehicle permits in Europe and Singapore. The community is actively debating the company's long-term valuation compared to regional peers and Waymo, as investors look for clarity on 2026 growth targets and the impact of recent institutional accumulation.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and selling pressure following recent earnings, with the community actively debating whether the price action reflects a disconnect between strong fundamentals and market optics or a broader biotech sector sell-off. Investors are divided, with many expressing deep frustration over the lack of aggressive share buybacks and communication from leadership, while others see the current dip as a strategic accumulation opportunity given the company's long-term growth trajectory and potential for future M&A activity.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant downward pressure and intense community debate as investors grapple with a sharp post-earnings sell-off that has defied positive analyst sentiment. Shareholders are actively questioning whether the volatility is driven by broader market instability and geopolitical tensions, or if it reflects deeper concerns over potential management alignment with a low-cost acquisition strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of Stock

Nuvilex Inc. (NASDAQ:PMCB - Get Free Report) Director Jonathan Schechter purchased 20,000 shares of Nuvilex stock in a transaction that occurred on Monday, January 5th. The shares were bought at an...

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Current Price	$0.7227
Prev Close	$0.6868
Open	$0.6868
Dividend Yield	0.00%
50-Day Moving Average	$0.7696
Beta	0.70
Avg. Volume	150,953.53
PE Ratio	-0.66

52-Week High	$1.64
52-Week Low	$0.63
Market Capitalization	$7.37M
EPS (Annual)	$3.19
Price to Book	0.19
Revenue Per Employee	$0.00

PMCB
PharmaCyte Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PMCB News

PMCBPharmaCyte Biotech Inc